Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $33.50 Average PT from Analysts
Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have received a consensus recommendation of “Buy” from the six research firms that are covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have issued ratings on the stock in […]
More Stories
Democratic Rep. Cherfilus-McCormick Resigns Ahead of Ethics Committee Sanctions Hearing
By Chase Smith Rep. Sheila Cherfilus-McCormick (D-Fla.) resigned from Congress on Tuesday, stepping down hours before the House Ethics Committee...
Is Hell’s Paradise Season 3 Renewed? Release Date, Plot, and Episodes
With the recent release of the anime series Hell’s Paradise, fans are curious to know about the renewal status of...
Who is Lana Condor? Movies and Controversy at the Fashion Trust Awards Show
From an orphanage to becoming a well-known face in the American film industry, Lana has come a long way. Want...
Bridgerton Season 5: Release Date, Cast, Teaser, and Recent Updates
Fans’ favourite series, Bridgerton season 5, is coming back soon. The series’ official network, Netflix, has officially announced the renewal....
CBP to Begin First Phase of Tariff Refunds Following Supreme Court Ruling
By Aldgra Fredly U.S. Customs and Border Protection (CBP) is set to begin the first phase of its refund process...
2 US Embassy Employees, 2 Mexican Officials Killed in Car Crash
By Aldgra Fredly Two instructor officers from the U.S. Embassy in Mexico and two Mexican officials died in a car...